GlassScriptPhysician profile
Judith A Heilman
NPI 1255395737
$2,156.42
in general payments reported to CMS, 2019-2025
19 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $542 · 2023: $302 · 2024: $715 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $568.30 | 2021-2024 | Farxiga |
| Vifor Pharma, INC. | $320.54 | 2021-2022 | |
| Fresenius USA Marketing, INC. | $286.35 | 2021-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $211.10 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Opko Pharmaceuticals, LLC | $203.56 | 2021-2023 | Rayaldee |
| Akebia Therapeutics INC | $117.49 | 2021-2025 | Vafseo |
| Otsuka America Pharmaceutical, INC. | $89.35 | 2022-2024 | Jynarque |
| Amgen INC. | $61.08 | 2021 | |
| Aurinia Pharma U.S., INC. | $42.29 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.86 | 2021-2022 | |
| Novo Nordisk INC | $34.19 | 2023-2024 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $30.57 | 2024 | |
| Alnylam Pharmaceuticals INC. | $26.42 | 2021 | |
| Travere Therapeutics, INC. | $25.72 | 2024 | |
| Calliditas Therapeutics US INC. | $22.64 | 2023 | Tarpeyo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.59 | 2022 | |
| Chiesi USA, INC. | $21.05 | 2023 | Cleviprex |
| Lilly USA, LLC | $17.35 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $16.97 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Heilman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.